COVID-19 Treatments Locator Tool: Request to Health Care Providers

March 11, 2024

Dear Valued Provider,

If you are a health care partner who offers Paxlovid (nirmatrelvir co packaged with ritonavir), Lagevrio (molnupiravir), or Veklury (remdesivir) for outpatient use, the Administration for Preparedness and Response, part of the U.S. Department of Health and Human Services (HHS), encourages your participation in a COVID-19 treatments locator to improve provider and patient access to these medications.

By opting in to the COVID-19 Treatments Locator, you can ensure providers and patients can quickly find the closest location with availability of these medications that decrease the risk of severe illness, hospitalization and death from COVID-19. Sites with an account in the Health Partners Ordering Portal (HPOP) can leverage that account to voluntarily indicate availability (yes/no) of commercial outpatient COVID-19 therapeutics. Those without HPOP accounts can do so using the voluntary reporting website.

Only the information you provide will be visible on the locator. Your site can opt out of being on the locator at any time. Being on the locator requires minimal engagement: provide your location information, note which COVID-19 outpatient treatments your site has available, and agree to be visible on the locator. Participation does not constitute an agreement to share any other data with HHS. To remain on the locator, sites are encouraged to note availability as often as they can, such as weekly or monthly, but would need to denote availability (yes/no) at least once every 60 days. After 60 days without noting that the site has treatments available, the site is removed from the locator. We also encourage you to keep the services offered at your site, such as test to treat or telehealth services, up to date on the Treatments Locator to improve patient access to these options when available.

Please contact COVID19.Therapeutics@hhs.gov with any questions.